Cellectar Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.About CLRB
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
CEOJames V. Caruso
CEOJames V. Caruso
Employees11
Employees11
HeadquartersFlorham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded1996
Founded1996
Employees11
Employees11
CLRB Key Statistics
Market cap16.25M
Market cap16.25M
Price-Earnings ratio-0.25
Price-Earnings ratio-0.25
Dividend yield—
Dividend yield—
Average volume79.65K
Average volume79.65K
High today$5.35
High today$5.35
Low today$5.04
Low today$5.04
Open price$5.14
Open price$5.14
Volume47.58K
Volume47.58K
52 Week high$67.50
52 Week high$67.50
52 Week low$4.11
52 Week low$4.11
CLRB News
TipRanks 7d
Cellectar Biosciences, ITM enter supply agreement for GMP-grade Ac-225Cellectar Biosciences (CLRB) and ITM Isotope Technologies Munich announced a supply agreement for Actinium-225, Ac-225. The agreement will support the clinical...
People also own
Based on the portfolios of people who own CLRB. This list is generated using Robinhood data, and it’s not a recommendation.